Cite
HARVARD Citation
Banerjee, S. et al. (n.d.). 518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers. International journal of gynecological cancer. pp. A86-A87. [Online].